CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
07 May 2020 - 10:00PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that Samarth Kulkarni, Ph.D., Chief
Executive Officer of CRISPR Therapeutics, is scheduled to present
at the virtual Bank of America Securities 2020 Health Care
Conference on Thursday, May 14, 2020, at 11:40 a.m. ET.
A live webcast of the fireside chat will be available on the
"Events & Presentations" page in the Investors section of the
Company's website at https://crisprtx.com/events. A replay of the
webcast will be archived on the Company's website for 14 days
following the presentation.
About CRISPR TherapeuticsCRISPR Therapeutics is
a leading gene editing company focused on developing transformative
gene-based medicines for serious diseases using its proprietary
CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing
technology that allows for precise, directed changes to genomic
DNA. CRISPR Therapeutics has established a portfolio of therapeutic
programs across a broad range of disease areas including
hemoglobinopathies, oncology, regenerative medicine and rare
diseases. To accelerate and expand its efforts, CRISPR Therapeutics
has established strategic partnerships with leading companies
including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR
Therapeutics AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and
R&D operations based in Cambridge, Massachusetts, and business
offices in San Francisco, California and London, United Kingdom.
For more information, please visit www.crisprtx.com.
Investor Contact:Susan
Kimsusan.kim@crisprtx.com
Media Contact:Rachel Eides WCG on behalf of
CRISPR617-337-4167reides@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2024 to May 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From May 2023 to May 2024